focus -WSS

focus

author：focus 2025-09-30 19:03:23 - browse：4448

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： When a patient nears the end, a feared therapy can comfort

WSS

Scientists grapple with ethics of stem cell research

A new ‘biological computer' targets cancer while sparing healthy cells

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

In rare move, senator releases unverified FBI source report alleging Biden bribe

How to save health care price transparency rules

Sanders wants to replace patents with prizes for drug inventions

leisure time

focus

knowledge

In age of alternative facts, a scholarly course on calling out crap

A new ‘biological computer' targets cancer while sparing healthy cells

Medicare details structure of new drug price negotiation program

'CMA Fest' 2023: How to watch, who is performing and more

Medicare details structure of new drug price negotiation program

John Green on his newest strategy for fighting tuberculosis

State Dept. review finds Biden bears some blame for Afghanistan failures

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Supreme Court strikes down use of affirmative action

Why scientists need input from humanists on sensitive research

hotspot

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Change Healthcare outage fallout shows need for new oversight

The stock market has soared this year, but will it last? Experts weigh in

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Scientists grapple with ethics of stem cell research

focus

Wikipedia

hotspot

focus